Nicole M. Sodir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole M. Sodir has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Danilo Maddalo
Department of Translational Oncology, Genentech, South San Francisco, CA, USA.
43 shared publications - Eva Lin
18Molecular Discovery Cancer Cell Biology, Genentech, South San Francisco, California
38 shared publications - Jeffrey T. Lau
17 In Vivo Pharmacology Department, Genentech, South San Francisco, California
38 shared publications - Anwesha Dey
Genentech
32 shared publications - Marc Hafner
Discovery Oncology, Genentech, South San Francisco, CA 94080, USA; Computational Sciences Center of Excellence, Genentech, South San Francisco, CA 94080, USA
32 shared publications - Katherine E. Hutchinson
15Department of Translational Medicine, Genentech, South San Francisco, California
31 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
Base editor tiling of the PTPN11 gene identifies resistance variants to SHP2 inhibitors
- 18 November 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
Open AccessBase editor tiling of the PTPN11 gene identifies resistance variants to SHP2 inhibitors
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Effect of FGFR2-selective inhibitor and non-selective inhibitor infigratinib on normalized growth and downstream FGFR signaling
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Effect of FGFR2-selective inhibitor and non-selective inhibitor infigratinib on normalized growth and downstream FGFR signaling
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
FGFR2 alterations co-occur with PIK3CAmut in breast tumors
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
FGFR2 alterations co-occur with PIK3CAmut in breast tumors
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Evaluation of the anti-tumor activity of FGFR2 inhibitor in combination with inavolisib in MFM223x2.2 xenograft model
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Evaluation of the anti-tumor activity of FGFR2 inhibitor in combination with inavolisib in MFM223x2.2 xenograft model
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Growth rate inhibition metrics
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Growth rate inhibition metrics
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Foundation Medicine (FMI) FoundationACT (FACT) panel of NGS features selected by model as associated with response
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Foundation Medicine (FMI) FoundationACT (FACT) panel of NGS features selected by model as associated with response
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Drug combination effect of inavolisib and the FGFR2i as measured by a two-way 10 x 8 serial dilution matrix in a 5-day viability assay
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Drug combination effect of inavolisib and the FGFR2i as measured by a two-way 10 x 8 serial dilution matrix in a 5-day viability assay
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Relationship between FGFR2 expression and inavolisib sensitivity and pAKT S473 baseline expression
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Relationship between FGFR2 expression and inavolisib sensitivity and pAKT S473 baseline expression
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Prevalence of FGFR2 alterations in conjunction with single and multiple PIK3CAmut breast and pan-solid tumor tissue biopsies
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Prevalence of FGFR2 alterations in conjunction with single and multiple PIK3CAmut breast and pan-solid tumor tissue biopsies
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
FGFR2 ectopic expression potentiates inavolisib mediated mutant p110α degradation and enhance PI3K activity more than matched control cells
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
FGFR2 ectopic expression potentiates inavolisib mediated mutant p110α degradation and enhance PI3K activity more than matched control cells